BEVC | Activity | F4

Introducing F4 Champions, a new accelerator for founders at the earliest stage.F4 Champions for early-stage foundersEnrollment closesAugust 2Learn more

Team Portfolio Raise Champions Essays

F4/BEVC/Activity

BEVC Activity

Every public signal F4 has attached to this firm, with sources and cross-entity links.

Types

Time range

3 milestones· APR 2026 – MAY 2026Show all

Milestone

Portfolio company Addition Therapeutics presented preclinical proof-of-concept data at the ASGCT 29th Annual Meeting.

Addition Therapeutics

Addition Therapeutics BEVC

additiontx.comMAY 12, 2026

MAY 12, 2026

Milestone

Portfolio company Addition Therapeutics announced multiple oral and poster presentations at the ASGCT 29th Annual Meeting.

Addition Therapeutics

Addition Therapeutics BEVC

additiontx.comAPR 27, 2026

APR 27, 2026

Milestone

Portfolio company PinkDx published evidence in the International Journal of Gynecological Cancer on endometrial cancer detection using a vaginal swab.

PinkDx

PinkDx BEVC

pinkdx.comAPR 6, 2026

APR 6, 2026

News

Portfolio company PinkDx's scientific breakthrough in endometrial cancer detection was featured on Good Morning America.

PinkDx

PinkDx BEVC

pinkdx.comAPR 3, 2026

APR 3, 2026

4 milestones· MAR 2025 – DEC 2025Show all

Milestone

Portfolio company Addition Therapeutics announced $100M in funding to advance its genomic medicine pipeline for chronic and rare diseases.

Addition Therapeutics

Addition Therapeutics BEVC

additiontx.comDEC 17, 2025

DEC 17, 2025

Milestone

Portfolio company Montara Therapeutics announced its first BrainOnly-enabled development candidate for TSC-related epilepsy and appointed a Chief Business Officer.

Montara Therapeutics

Montara Therapeutics BEVC

montaratx.comDEC 8, 2025

DEC 8, 2025

Milestone

Portfolio company Montara Therapeutics received a grant from The Michael J. Fox Foundation to develop treatments using its BrainOnly platform.

Montara Therapeutics

Montara Therapeutics BEVC

montaratx.comMAY 21, 2025

MAY 21, 2025

Milestone

Portfolio company Montara Therapeutics closed a $20M oversubscribed seed expansion and appointed Troy Wilson as Chairman of the Board.

Montara Therapeutics

Montara Therapeutics BEVC

montaratx.comMAR 13, 2025

MAR 13, 2025

Investment

Joined PinkDx's upsized Series A second close alongside Blue Venture Fund and Sandbox Clinical Ventures.

PinkDx

PinkDx BEVC

pinkdx.comJAN 23, 2025

JAN 23, 2025

New Fund

Filed with the SEC to raise a $25M climate-focused fund, extending beyond its life sciences roots.

$25M climate-focused fund (SEC filing)

BEVC

techcrunch.comAUG 2024

AUG 2024

Milestone

Portfolio company Radar Therapeutics raised $13.4M in seed funding to develop smart programmable medicines using molecular RNA sensors.

Radar Therapeutics

Radar Therapeutics BEVC

businesswire.comMAY 23, 2024

bakarlabs.berkeley.edu

MAY 23, 2024

Milestone

Portfolio company Insamo launched with $12M in funding from Playground Global, venBio, and MRL Ventures Fund to develop macrocyclic peptide drugs.

Insamo Therapeutics

Insamo Therapeutics BEVC

businesswire.comFEB 21, 2024

FEB 21, 2024